Stock CNTA CENTESSA PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
8.89 USD 0.00% Intraday chart for Centessa Pharmaceuticals plc +4.40% +11.68%
06-21 Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $11 From $8, Maintains Equalweight Rating MT
06-10 Centessa Pharmaceuticals Appoints John Crowley as CFO MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Centessa Pharmaceuticals plc Announces Executive Changes
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
Centessa Pharmaceuticals plc Announces Open IND for ORX750
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio
Anaptysbio, Inc. Enters into License Agreement with Centessa Pharmaceuticals (UK) Limited
Centessa Pharmaceuticals' Q3 Loss Narrows
Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
Centessa Pharmaceuticals plc Announces Executive Appointments
Centessa Pharmaceuticals Insider Sold Shares Worth $235,688, According to a Recent SEC Filing
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CNTA Stock
  4. News Centessa Pharmaceuticals plc
  5. Other languages